FIELD: medicine.
SUBSTANCE: invention refers to neurology, and can be used to reduce the expression of the mutant hauntingtin gene (mHTT) to reduce or prevent the formation of Htt aggregates in a subject with Huntington's disease (HD). That is ensured by administering a polynucleotide encoding a repressor of a mutant allele Htt (mHtt) into a striatum of a subject, wherein the repressor contains a "zinc finger" protein designated 30640, 30645 or 33074, wherein the polynucleotide comprises an adeno-associated viral vector (AAV) introduced in 2x1010 vector genomes, where the transcription factor repressor reduces mHtt expression by at least 85 % in HD-neurons in the subject's striatum.
EFFECT: invention provides reduction and/or elimination of aggregation of Huntingtin (Htt), reduced motor defects, increased cell activity (for example, ATP activity) and / or reduced apoptosis in a subject with HD.
7 cl, 7 dwg, 3 tbl, 6 ex
Title | Year | Author | Number |
---|---|---|---|
METHODS AND COMPOSITIONS FOR TREATING HUNTINGTON'S DISEASE | 2014 |
|
RU2693891C1 |
METHODS AND COMPOSITIONS FOR HUNTINGTON DISEASE TREATMENT | 2013 |
|
RU2639277C2 |
TAU MODULATORS AND METHODS AND COMPOSITIONS FOR THEIR DELIVERY | 2017 |
|
RU2789459C2 |
CELL TARGETING MEDIATED BY CHIMERIC ANTIGEN RECEPTOR | 2018 |
|
RU2783316C2 |
METHODS AND COMPOSITIONS FOR THE TREATMENT OF FABRY DISEASE | 2017 |
|
RU2788133C2 |
METHODS AND COMPOSITIONS FOR TREATING FABRY DISEASE | 2020 |
|
RU2822369C2 |
MODIFICATION OF B-CELLS | 2018 |
|
RU2783116C2 |
FAD2 PERFORMANCE LOCI AND CORRESPONDING TARGET SITE SPECIFIC BINDING PROTEINS CAPABLE OF INDUCING TARGETED BREAKS | 2013 |
|
RU2656158C2 |
TARGETED MODIFICATION OF MALATE DEHYDROGENASE | 2013 |
|
RU2658437C2 |
AAV-BASED HUNTINGTON'S DISEASE TREATMENT | 2017 |
|
RU2749971C2 |
Authors
Dates
2019-06-11—Published
2015-05-07—Filed